Lagerstandorte

New Jersey, USA
Czech Republic, EU
Mumbai, India

* Vorbehaltlich Verfügbarkeit

Dokumentation

MSDS herunterladen

Beispiel-COA herunterladen

Enthält: HPLC, MASS/LC-MS, 1H-NMR, FT-IR, Gehalt, Structure Elucidation Report (SER) sowie zusätzliche analytische Daten je nach Produkt.

176161-18-5Maribavir Impurity 4

● Auf Lager

Katalog-Nr.::	VE0028050
CAS-Nr.::	176161-18-5
Summenformel::	C18H17BrCl2N2O7
Molare Masse::	524.15 g/mol

Angebot anfordern

Zur RFQ-Liste hinzufügen

Zusätzliche Informationen zu CAS 176161-18-5

Parent drug

Maribavir

IUPAC-Name

(2S,3S,4S,5S)-2-(Acetoxymethyl)-5-(2-bromo-5,6-dichloro-1H-benzo[d]imidazol-1-yl)tetrahydrofuran-3,4-diyl diacetate

Pharmacopeial Synonyms

N/A

Synonyme

N/A

SMILES

BrC1=NC2=CC(Cl)=C(Cl)C=C2N1[C@@H](O[C@H]3COC(C)=O)[C@@H](OC(C)=O)[C@H]3OC(C)=O

InChI

InChI=1S/C18H17BrCl2N2O7/c1-7(24)27-6-14-15(28-8(2)25)16(29-9(3)26)17(30-14)23-13-5-11(21)10(20)4-12(13)22-18(23)19/h4-5,14-17H,6H2,1-3H3/t14-,15-,16-,17-/m0/s1

Beschreibung

Maribavir Impurity 4 (CAS 176161-18-5) is a process-related and degradation impurity detected during maribavir synthesis and stability testing. Identified and quantified by HPLC, LC-MS and 1H/13C NMR, it shows a reproducible retention time and characteristic mass fragmentation useful for trace-level monitoring. Elucidation of its formation pathways, including incomplete reaction intermediates or oxidative degradation, supports targeted mitigation strategies. Available analytical data on solubility, thermal behavior, and detector response factors enable robust method validation, forced-degradation studies and specification setting to control impurity levels and ensure compliance with regulatory quality expectations.